VRDN FY 2022 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-40.2% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$134M-7579.2% margin

Net Income

-$130M-7329.2% margin

EPS (Diluted)

$-3.91

Cash Flow

Operating Cash Flow

-$94M

Free Cash Flow

-$95M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$435M

Total Liabilities

$40M

Stockholders' Equity

$395M

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-40.2%
Gross Profit	$2M	$3M	-40.2%
Operating Income	-$134M	-$80M	-68.5%
Net Income	-$130M	-$79M	-63.5%